(MedPage Today) — Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) — both under Medicare Advantage and in separate Part D plans — is likely to leave many patients wanting, researchers…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
